HH-009

The main objectives of the dose escalation phase (Ia): 1) To evaluate the safety and tolerability of HH-009 injection in the treatment of advanced solid tumors; 2) To determine the maximum tolerated dose (MTD) and/or the recommended dose for the dose expansion phase of HH-009 injection in the treatment of advanced solid tumor subjects. The main objectives of the dose expansion phase (Ib): 3) To determine the Phase II recommended dose (RP2D) of HH-009 injection in the treatment of advanced hepatocellular carcinoma (HCC) and other solid tumor subjects.

Evaluate the efficacy of HH-009 injection for FGF19-positive patients with advanced or unresectable hepatocellular carcinoma (HCC) that has progressed after failure of prior systemic therapy.